Trailing-twelve-month (TTM) revenue is $64.39 Billion with a year-over-year growth of +10.39%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $15,776,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-04 |
| Q4 FY2025Period ended 2025-12-31 | $16,618,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-20 |
| Q1 FY2026Period ended 2026-03-31 | $15,002,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-08 |
| Q2 FY2026Period ended 2026-06-30 | $16,990,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-03 |
| TTM revenue | $64,386,000,000 |
Current P/S: $445,708,832,502 market capitalization ÷ $64,386,000,000 TTM revenue = 6.92x.
Market capitalization source: FMP quote. Quote observed 2026-09-10T15:05:22.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $16.99B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-10T15:05:22.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Alphagan/Combigan | $326M | $529M | $346M | $272M | $248M | $197M |
| Botox Cosmetic | $1.1B | $2.2B | $2.6B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Non-US | $10.9B | $12.7B | $12.3B | $12.4B | $13.3B | $2.4B |
| UNITED STATES | $34.9B | $43.5B | $45.7B | $41.9B |
$64.39B
$64.39 Billion
+10.39%
vs. $58.33B a year ago (TTM)
+3.69%
5 Year compound annual growth rate
1 Year
+10.39%
3 Year
+4.75%
5 Year
+3.69%
10 Year
+10.03%
15 Year
+9.52%
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $61.16B | +$4.83B | +8.57% |
| 2024 | $56.33B | +$2.02B | +3.71% |
| 2023 | $54.32B | ($3.74B) | (6.44%) |
| 2022 | $58.05B | +$1.86B | +3.30% |
| 2021 | $56.20B | +$10.39B | +22.69% |
| 2020 |
TTM Growth
+10.39%
3-Year CAGR
+4.75%
5-Year CAGR
+3.69%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-10T15:05:22.000Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-09.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $2.7B |
| $2.6B |
| Botox Therapeutic | $1.4B | $2.5B | $2.7B | $3.0B | $3.3B | $3.8B |
|---|
| Duodopa | $494M | $511M | $458M | $468M | $447M | $381M |
|---|
| H U M I R A | $19.8B | $20.7B | $21.2B | $14.4B | $9.0B | $4.5B |
|---|
| Imbruvica | $5.3B | $5.4B | $4.6B | $3.6B | $3.3B | $2.9B |
|---|
| Juvederm Collection | $718M | $1.5B | $1.4B | $1.4B | $1.2B | $993M |
|---|
| Linzess/Constella | $667M | $1.0B | $1.0B | $1.1B | $954M | $907M |
|---|
| Lumigan/Ganfort | $378M | $579M | $514M | $432M | $429M | $410M |
|---|
| MAVYRET | $1.8B | $1.7B | $1.5B | $1.4B | $1.3B | $1.3B |
|---|
| Other Aesthetics | $760M | $1.5B | $1.3B | $1.2B | $1.3B | $1.3B |
|---|
| Other Eye Care | $693M | $1.2B | $1.2B | $803M | $847M | $1.0B |
|---|
| Other Neuroscience | $539M | $685M | $475M | $276M | $338M | $207M |
|---|
| Other Products | $2.9B | $2.7B | $4.1B | $3.0B | $3.0B | $2.6B |
|---|
| Ozurdex | N/A | N/A | N/A | $472M | $494M | $493M |
|---|
| Qulipta | N/A | N/A | N/A | $408M | $658M | $1.0B |
|---|
| Restasis | $787M | $1.3B | $666M | $436M | $224M | N/A |
|---|
| RINVOQ | $731M | $1.7B | $2.5B | $4.0B | $6.0B | $8.3B |
|---|
| SKYRIZI | $1.6B | $2.9B | $5.2B | $7.8B | $11.7B | $17.6B |
|---|
| Ubrelvy | N/A | N/A | N/A | $815M | $1.0B | $1.3B |
|---|
| VENCLEXTA | $1.3B | $1.8B | $2.0B | $2.3B | $2.6B | $2.8B |
|---|
| Vraylar | N/A | N/A | $2.0B | $2.8B | $3.3B | $3.6B |
|---|
| $46.6B |
| $45.80B |
| +$12.54B |
| +37.69% |
| 2019 | $33.27B | +$513.00M | +1.57% |
| 2018 | $32.75B | +$4.54B | +16.08% |
| 2017 | $28.22B | +$2.58B | +10.06% |
| 2016 | $25.64B | +$2.78B | +12.16% |
